Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 2Hematologic Neoplasms 2Granuloma, Plasma Cell 2Rhabdomyosarcoma 1Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, B-Cell 1Glioblastoma 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Cyclophosphamide 34fludarabine 25fludarabine phosphate 24Tacrolimus 24Mycophenolic Acid 23Whole-Body Irradiation 22Busulfan 15Methotrexate 12Melphalan 12Granulocyte Colony-Stimulating Factor 12Antilymphocyte Serum 12thymoglobulin 11Cyclosporine 11Stem Cell Transplantation 10Filgrastim 10Rituximab 9Thiotepa 7Peripheral Blood Stem Cell Transplantation 7Nivolumab 7Dexamethasone 7trametinib 6Radiotherapy 6Mesna 6Cytarabine 6Prednisone 5Calcium Dobesilate 5Bortezomib 5Azacitidine 5Alemtuzumab 5Voriconazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Hematologic Neoplasms × ceritinib × Clear all
NCT02186821 2021-04-08

SIGNATURE

Novartis

Phase 2 Terminated
47 enrolled 13 charts
LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡